Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The adverse events atlas, towards a strategy to predict synergistic adverse events of combination therapies

AACR Annual Meeting 2022

Published: 13 Apr 2022

Views: 105

Rating:

Save

Prof Bart Westerman - Amsterdam UMC, Amsterdam, Netherlands

Prof Bart Westerman speaks to ecancer about an abstract that he presented at AACR 2022 regarding the development of a 'drug atlas'.

He explains that the 'drug atlas' creates a way to identify the synergistic interactions of drugs and allows a filter of preclinical data for the most effective combinations with the least toxicities.

Prof Westerman details how the model was developed and how it is progressing to someday be applied in the clinic.

Related Videos

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

Choosing Wisely in pathology

Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in pathology ( Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death

Dr Joshua Choe - Columbia University, New York City, USA

Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death ( Dr Joshua Choe - Columbia University, New York City, USA )

Genomic testing: Australian model for unlocking the potential of precision oncology for patients and health systems

Prof David Thomas - The Garvan Institute of Medical Research, Darlinghurst, Australia

Genomic testing: Australian model for unlocking the potential of precision oncology for patients and health systems ( Prof David Thomas - The Garvan Institute of Medical Research, Darlinghurst, Australia )

More from ecancer